Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure

MLA

Foster, Graham R., et al. “Sustained Virologic Response Rates with Telaprevir by Response after 4weeks of Lead-in Therapy in Patients with Prior Treatment Failure.” Journal of Hepatology, vol. 58, no. 3, Mar. 2013, pp. 488–94. EBSCOhost, https://doi.org/10.1016/j.jhep.2012.11.013.

APA

Foster, G. R., Zeuzem, S., Andreone, P., Pol, S., Lawitz, E. J., Diago, M., Roberts, S., Pockros, P. J., Younossi, Z., Lonjon-Domanec, I., De Meyer, S., Luo, D., George, S., Beumont, M., & Picchio, G. (2013). Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure. Journal of Hepatology, 58(3), 488–494. https://doi.org/10.1016/j.jhep.2012.11.013

Chicago

Foster, Graham R., Stefan Zeuzem, Pietro Andreone, Stanislas Pol, Eric J. Lawitz, Moises Diago, Stuart Roberts, et al. 2013. “Sustained Virologic Response Rates with Telaprevir by Response after 4weeks of Lead-in Therapy in Patients with Prior Treatment Failure.” Journal of Hepatology 58 (3): 488–94. doi:10.1016/j.jhep.2012.11.013.